Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192452 · ClinicalTrials.gov registry record · Phase 2
Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00192452 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 120 participants.
The verdict
NCT00192452, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
\- The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8 infusions.
Interventions
- DRUG MEDI-507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2001-03 |
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192452
The ClinicalTrials.gov registry entry for NCT00192452 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI-507 is the first listed.
NCT00192452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00192452 about?
NCT00192452 is a clinical study titled "Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis". \- The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8 infusions.
What is the current status of trial NCT00192452?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2001-03. Estimated completion is 2001-12.
What interventions are being tested in trial NCT00192452?
The interventions under investigation include: MEDI-507 (DRUG).
Who is sponsoring clinical trial NCT00192452?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.